Implant Sciences Achieves First Drug Detection Sale
WILMINGTON, Mass., July 22, 2015 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that, in a landmark sale for the company, it has sold 32 of its QS-B220 desktop explosives and drugs trace detectors across eight correctional facilities in Mexico. The units, which are replacing competing systems, will be deployed for drug detection.
“As informed and experienced users of trace detection, these correctional facilities chose to replace competitors’ ETD systems with our QS-B220 due to Implant Sciences’ expertise in non-rad ETD technology,” said Dr. Darryl Jones, Vice President of Global Sales and Marketing for Implant Sciences. “Our Mexican customer was particularly impressed that our system has proven, in market after market, to deliver the highest performance and the lowest total cost of ownership and operation. We estimate that the size of the worldwide drug detection market is the range of hundreds of millions of dollars, and we are excited to have made our first sale in this arena to a country that requires high quality drug detection technology,” added Dr. Jones.
“Implant Sciences has been making significant inroads in the last year in the global aviation security market, and we are gratified to see that our value proposition and performance capabilities have now translated into other markets and applications as well,” stated Dr. Bill McGann, CEO of Implant Sciences. “Our ETD systems are able to be adopted in a variety of markets and deployment scenarios to enhance security and as tools to prevent illicit contraband trafficking and criminal activity. We believe, based on the superior performance and value proposition of our product, that we will continue to expand our presence in aviation security, prisons, and border security markets, as well as in other verticals in the future.”